Comprehensive 2025 RNA Sequencing Services Market Overview: Trends, Forecasts, and Growth Drivers

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the RNA Sequencing Services Market Through 2025?
The market size for RNA sequencing services has seen a considerable expansion lately. The projected growth is from $3.58 billion in 2024 to $4 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. The previous growth can be accredited to increasing requirements for individualized medicine, breakthroughs in bioinformatics tools, an escalating concentration on drug discovery and growth, a rising utilization of RNA sequencing in agricultural studies, and widespread applications in clinical diagnostics.

What's the Projected Size of the Global RNA Sequencing Services Market by 2029?
The market for RNA sequencing services is poised for substantial expansion in the upcoming years, with an estimated valuation of $6.13 billion in 2029, and a compound annual growth rate (CAGR) of 11.3%. Factors contributing to the market growth during the predicted time frame include advancements in single-cell RNA sequencing technologies, the incorporation of artificial intelligence and machine learning in data analysis, extended research on non-coding RNA biomarkers, an increased need for transcriptomic analysis in immunotherapy research, and enhanced partnerships between educational institutions and industries in genomic research. Significant trends projected for this period are the growing adoption of long-read sequencing, the use of cloud-based analysis platforms, increased demand for RNA splicing analysis, and the integration of multi-omics data.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rna-sequencing-services-global-market-report

Top Growth Drivers in the RNA Sequencing Services Industry: What's Accelerating the Market?
The growing interest in personalized medicine is a significant driving force for the RNA sequencing services market. Personalized medicine is characterized by the customization of medical treatment based on individual attributes, such as genetic makeup or lifestyle choices, to enhance efficacy and reduce negative effects. The increasing preference for personalized medicine arises from its potential to offer more effective therapies, advances in the field of genomics, heightened complexity of diseases, and regulatory backing. RNA sequencing services assist in distinguishing disease subtypes, identifying biomarkers and therapeutic targets, predicting therapy responses, and monitoring disease evolution and therapy outcomes. Personalized medicine approaches utilize RNA sequencing technologies to deliver personalized and effective medications that address the distinct molecular traits of individual patients. For example, as reported by the US-based non-profit organization, Personalized Medicine Coalition, in February 2024, the FDA (Food and Drug Administration) approved 16 new personalized therapies for patients suffering from rare diseases in 2023, a significant increase from only six in 2022. The newly sanctioned personalized therapies in 2023 also comprise seven cancer drugs and three for other diseases and ailments. Consequently, the escalating demand for personalized medicine is propelling the growth trajectory of the RNA sequencing services market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14991&type=smp

What Trends Will Shape the RNA Sequencing Services Market Through 2029 and Beyond?
Prominent businesses in the RNA sequencing services market are concentrating their efforts on automation in order to decrease any potential human errors, such as with the next-generation sequencing (NGS) assay, with the goal of improving efficiency and precision in data processing and analysis. The RNA next-generation sequencing (RNA-seq) assay is an instrumental tool extensively utilized in genomics and molecular biology for investigating the transcriptome of a biological specimen. For instance, Tempus, a US-based precision medicine technology firm, revealed its standalone RNA next-generation sequencing assay, Tempus xR in June 2023. This ground-breaking assay for solid tumors provides a meticulous examination of the transcriptome, drawing attention to clinically meaningful fusions in over 100 specific genes, along with changes in splicing for MET Exon 14 and EGFRvIII. Acknowledging the relevance of RNA sequencing data, Tempus has traditionally integrated both DNA and RNA sequencing in their signature xT wide-range panel assay. Currently, clients have the liberty to request each test separately or concurrently while having the capacity to pair xR with selected Tempus algorithmic tests. This service suits physicians particularly interested in RNA fusions or modified splicing, as well as providers, researchers, and bio-pharma companies vying for an in-depth RNA sequencing examination of their existing specimens.

What Are the Main Segments in the RNA Sequencing Services Market?
The RNA sequencing services market covered in this report is segmented -

1) By Type: Ribosomal RNA (rRNA), Transfer RNA (tRNA), Long non-coding RNA (lncRNA)
2) By Sequencing Method: Next Generation Sequencing Methods, Other Sequencing Methods
3) By Application Area: Research Purposes, Diagnostic Purposes
4) By End Users: Academic And Government Institutes And Research Centers, Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:
1) By Ribosomal RNA (rRNA): Total RRNA Sequencing, RRNA Depletion
2) By Transfer RNA (tRNA): TRNA Profiling, TRNA Sequencing
3) By Long Non-Coding RNA (lncRNA): lncRNA Profiling, lncRNA Sequencing

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14991&type=smp

Which Top Companies are Driving Growth in the RNA Sequencing Services Market?
Major companies operating in the RNA sequencing services market are Thermo Fisher Scientific Inc., Feng Chi Biotech Corp., Illumina Inc., Qiagen NV, BGI Genomics Co. Ltd., Azenta Inc., Abcam Limited, Novogene Co. Ltd., Genewiz Inc., Diagenode LLC, CD Genomics, CeGaT GmbH, Lexogen GmbH, BaseClear BV, Active Motif Inc., Microsynth AG, RayBiotech Inc., Genomax Technologies Pte. Ltd., Phalanx Biotech Group Inc., Creative Biogene, SeqMatic LLC, Genohub Inc., Otogenetics, LC Sciences, Admera Health, Arraystar Inc., IGA Technology, Yaazh Xenomics

Which Regions Will Dominate the RNA Sequencing Services Market Through 2029?
North America was the largest region in the RNA sequencing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the RNA sequencing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14991

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.